Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

pembrolizumab 223Carboplatin 219Cisplatin 206Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 115Pemetrexed 102Dexamethasone 102Cyclophosphamide 102Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 92Fluorouracil 88Bevacizumab 84Nivolumab 74Leucovorin 73Rituximab 71Vincristine 68durvalumab 66Lenalidomide 64Radiation 62Etoposide 62atezolizumab 61Irinotecan 61130-nm albumin-bound paclitaxel 58Prednisone 57Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Medrol Veriderm × 1 year × Clear all
NCT03007147 2026-05-04

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 3 Active not recruiting
475 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡